Leukemia research最新文献

英文中文

Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review 皮肤黑色素瘤与血液系统恶性肿瘤并发的流行病学和遗传学研究：荟萃分析综述。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-26 DOI: 10.1016/j.leukres.2024.107610

Background

The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).

Aim

This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.

Methodology

A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.

The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).

Results

Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.

Conclusion

This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.

背景：近年来，由于早期诊断的进步和生存期的延长，癌症幸存者的人数不断增加。现有文献表明，皮肤黑色素瘤（CM）与血液系统恶性肿瘤（HM）之间存在联系。研究目的：本研究旨在审查关于皮肤黑色素瘤与血液系统恶性肿瘤之间联系的流行病学研究，并探讨导致这种联系的遗传、生物和环境因素：方法：进行文献综述和荟萃分析，评估 HM 后患 CM 的风险，反之亦然。纳入研究的数据均报告了标准化发病率比（SIR）或危险比（HR）及95%置信区间（CI），研究采用随机效应模型对这些数据进行了汇总。使用 I² 和 Cochrane Q 检验统计量评估研究之间的异质性。采用随机效应模型对发病率数据进行了汇总。本综述已在 PROSPERO（CRD42022359887）上注册：10项研究的重点是CM患者的HM诊断，包括189094人的合并队列，11项研究的重点是HM患者的CM诊断，包括306967人的队列。CM 后 HM 的 SIR 在 1.25 到 3.12 之间，而 HM 后 CM 的 SIR 在 0.83 到 4.12 之间。合并 CM 患者中 HM 的比例为 62.4%，合并 HM 患者中 CM 的比例为 19.6%。统计异质性很高，I²值分别为99.19%和89.15%：本综述证实了同一患者的 CM 和 HM 之间存在关联。这种关联主要归因于涉及 BRAF-V600K、酪氨酸激酶通路基因、CDKN2A (P16) 和 BCL-2 的遗传因素。此外，紫外线辐射和免疫功能受损等风险因素也与这些癌症的发病率有关。

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology 利用微细胞技术对原发性多发性骨髓瘤细胞的药物反应进行体外测试

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-26 DOI: 10.1016/j.leukres.2024.107599

Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of in vitro drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and in vitro drug response of primary myeloma cells was analyzed. In vitro responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability in vitro. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy in vitro. To further validate these in vitro results against in vivo outcomes, screening a larger cohort is necessary.

多发性骨髓瘤是一种浆细胞侵袭性肿瘤。虽然许多药物已获得批准，但缺乏针对个体药物反应的既定预测指标构成了挑战。在这项研究中，我们探索了基于微波和荧光的 Cellply CC-Array® 技术，该技术可用于体外药物反应的高通量分析，是患者治疗效果的潜在预测标志物。此外，我们还研究了该技术在评估效应细胞有效性方面的应用。我们从 22 名患者的骨髓中分离出单核细胞，分析了原发性骨髓瘤细胞的体外药物反应。原代患者样本对美法仑、硼替佐米和地塞米松的体外反应与患者的临床反应相关。由于骨髓瘤体外存活率低导致培养时间有限，这种方法在确定对来那度胺、达拉曲单抗和艾洛妥珠单抗的敏感性方面存在局限性。通过分析细胞接近性，该平台能够评估 NK 和 T 细胞的个体抗肿瘤活性。总之，CC-Array 微阵列技术可以在体外评估骨髓瘤细胞对用于多发性骨髓瘤治疗的特定药物的反应。为了进一步验证这些体外结果与体内结果的一致性，有必要对更大的群体进行筛选。

{"title":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","authors":"","doi":"10.1016/j.leukres.2024.107599","DOIUrl":"10.1016/j.leukres.2024.107599","url":null,"abstract":"<div><div>Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of <em>in vitro</em> drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and <em>in vitro</em> drug response of primary myeloma cells was analyzed. <em>In vitro</em> responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability <em>in vitro</em>. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy <em>in vitro</em>. To further validate these <em>in vitro</em> results against <em>in vivo</em> outcomes, screening a larger cohort is necessary.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis 体重指数对慢性白血病患者服用博舒替尼安全性的影响：事后汇总数据分析。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-24 DOI: 10.1016/j.leukres.2024.107609

引用次数: 0

Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan Ruxolitinib在现实世界骨髓纤维化患者中的安全性和有效性：台湾一项为期两年的观察性研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-23 DOI: 10.1016/j.leukres.2024.107601

引用次数: 0

The phylogenetic age paradox of non-coding RNAs 非编码 RNA 的系统发育年龄悖论。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-22 DOI: 10.1016/j.leukres.2024.107600

引用次数: 0

A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure 骨髓细胞白血病 1 (MCL1) 抑制剂 tapotoclax (AMG 176) 对低甲基化药物治疗失败后骨髓增生异常综合征患者的 I 期研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-22 DOI: 10.1016/j.leukres.2024.107602

引用次数: 0

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study BCR::ABL1酪氨酸激酶抑制剂对慢性丙型肝炎病毒感染的癌症患者的病毒学效应和肝毒性：前瞻性研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-03 DOI: 10.1016/j.leukres.2024.107597

引用次数: 0

Therapeutic advances for the management of adult T cell leukemia: Where do we stand? 成人 T 细胞白血病的治疗进展：现状如何？

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-02 DOI: 10.1016/j.leukres.2024.107598

Adult T cell leukemia (ATL) is an aggressive blood malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-1) retrovirus. ATL encompasses four subtypes (acute, lymphoma, chronic, and smoldering), which exhibit different clinical characteristics and respond differently to various treatment strategies. Yet, all four subtypes are characterized by a dismal long-term prognosis and a low survival rate. While antiretroviral therapy improves overall survival outcomes in smoldering and chronic subtypes, survival remains poor in lymphoma subtypes despite their good response to intensive chemotherapy. Nonetheless, acute ATL remains the most aggressive form associated with profound immunosuppression, chemo-resistance and dismal prognosis. Targeted therapies such as monoclonal antibodies, epigenetic therapies, and arsenic/IFN, emerged as promising therapeutic approaches in ATL. Allogeneic hematopoietic cell transplantation is the only potentially curative modality, alas applicable to only a small percentage of patients. The recent findings demonstrating the expression of the viral oncoprotein Tax in primary ATL cells from patients with acute or chronic ATL, albeit at low levels, and their dependence on continuous Tax expression for their survival, position ATL as a virus-addicted leukemia and validates the rationale of anti-viral treatment strategies. This review provides a comprehensive overview on conventional, anti-viral and targeted therapies of ATL, with emphasis on Tax-targeted therapied in the pre-clinical and clinical settings.

成人 T 细胞白血病（ATL）是一种继发于人类 T 细胞白血病病毒 I 型（HTLV-1）逆转录病毒慢性感染的侵袭性血液恶性肿瘤。ATL 包括四种亚型（急性、淋巴瘤、慢性和烟雾型），它们表现出不同的临床特征，对各种治疗策略的反应也不尽相同。然而，这四种亚型的长期预后都很糟糕，存活率很低。抗逆转录病毒疗法可改善烟熏型和慢性亚型患者的总体存活率，而淋巴瘤亚型患者尽管对强化化疗反应良好，但存活率仍然很低。尽管如此，急性ATL仍然是最具侵袭性的淋巴瘤，具有严重的免疫抑制、化疗耐药和预后不良等特点。单克隆抗体、表观遗传疗法和砷/IFN等靶向疗法成为治疗ATL的有前途的方法。异基因造血细胞移植是唯一可能治愈的方法，但只适用于一小部分患者。最近的研究结果表明，急性或慢性 ATL 患者的原发性 ATL 细胞中存在病毒肿瘤蛋白 Tax 的表达（尽管水平较低），而且这些细胞的存活依赖于 Tax 的持续表达，这将 ATL 定义为一种病毒上瘾的白血病，并验证了抗病毒治疗策略的合理性。本综述全面概述了 ATL 的常规、抗病毒和靶向疗法，重点是临床前和临床环境中的 Tax 靶向疗法。

{"title":"Therapeutic advances for the management of adult T cell leukemia: Where do we stand?","authors":"","doi":"10.1016/j.leukres.2024.107598","DOIUrl":"10.1016/j.leukres.2024.107598","url":null,"abstract":"<div><div>Adult T cell leukemia (ATL) is an aggressive blood malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-1) retrovirus. ATL encompasses four subtypes (acute, lymphoma, chronic, and smoldering), which exhibit different clinical characteristics and respond differently to various treatment strategies. Yet, all four subtypes are characterized by a dismal long-term prognosis and a low survival rate. While antiretroviral therapy improves overall survival outcomes in smoldering and chronic subtypes, survival remains poor in lymphoma subtypes despite their good response to intensive chemotherapy. Nonetheless, acute ATL remains the most aggressive form associated with profound immunosuppression, chemo-resistance and dismal prognosis. Targeted therapies such as monoclonal antibodies, epigenetic therapies, and arsenic/IFN, emerged as promising therapeutic approaches in ATL. Allogeneic hematopoietic cell transplantation is the only potentially curative modality, alas applicable to only a small percentage of patients. The recent findings demonstrating the expression of the viral oncoprotein Tax in primary ATL cells from patients with acute or chronic ATL, albeit at low levels, and their dependence on continuous Tax expression for their survival, position ATL as a virus-addicted leukemia and validates the rationale of anti-viral treatment strategies. This review provides a comprehensive overview on conventional, anti-viral and targeted therapies of ATL, with emphasis on Tax-targeted therapied in the pre-clinical and clinical settings.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemotherapy and allo-HSCT for young patients with aggressive ATL 对侵袭性ATL年轻患者进行化疗和异基因造血干细胞移植。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-27 DOI: 10.1016/j.leukres.2024.107596

Adult T-cell leukemia-lymphoma (ATL) is an aggressive malignancy with a poor prognosis, especially for patients with the aggressive subtype. While conventional chemotherapy offers short-term disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most promising curative approach for young, transplant-eligible patients. This review focuses on current treatment strategies for aggressive ATL in this specific population. We discuss the rationale for early upfront allo-HSCT following induction chemotherapy. The advent of allo-HSCT using alternative donors, particularly haploidentical HCT, has broadened the applicability of early upfront allo-HSCT in patients with aggressive ATL worldwide. Finally, we address emerging therapies that may improve outcomes in the context of allo-HSCT, paving the way for further advancements in the treatment of aggressive ATL.

成人T细胞白血病淋巴瘤（ATL）是一种侵袭性恶性肿瘤，预后较差，尤其是侵袭性亚型患者。虽然传统化疗能在短期内控制病情，但对于符合移植条件的年轻患者来说，异基因造血干细胞移植（allo-HSCT）仍是最有希望治愈的方法。本综述将重点讨论目前针对这一特殊人群的侵袭性ATL的治疗策略。我们讨论了在诱导化疗后尽早进行前期allo-HSCT的理由。使用替代供者，尤其是单倍体同种异基因造血干细胞移植（HCT）的出现扩大了早期先期同种异基因造血干细胞移植在全球侵袭性 ATL 患者中的适用性。最后，我们探讨了可改善allo-HSCT治疗效果的新兴疗法，为进一步推动侵袭性ATL的治疗铺平了道路。

引用次数: 0

Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis 长非编码 RNA 在急性髓性白血病中的临床意义：系统回顾与荟萃分析

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-23 DOI: 10.1016/j.leukres.2024.107595

Background

Long noncoding RNAs (lncRNAs) may function as prognostic biomarkers in acute myeloid leukaemia (AML). However, it is still unknown exactly how significant lncRNAs are for the prognosis of AML. With a focus on their prognostic and therapeutic potential, the study aimed to provide a comprehensive review of the literature regarding the role of lncRNAs in AML.

Method

Pub Med, The Cochrane Library, Embase, Science Direct, Web of science, Scopus, and Google scholar were searched until November, 2023. Original publications of any type exploring the prognostic and therapeutic potential of lncRNAs in AML patients were included. Heterogeneity and publication bias were examined using the I² test and a funnel plot, respectively. To quantify the relationship between various lncRNA expression in AML patient survival, odds ratios (ORs) or hazards ratios (HRs) with 95 % confidence intervals (CIs) were pooled. Quality of studies was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI).

Results

Twenty-seven studies including 5665 subjects were selected for the final analysis. In patients with AML, abnormal lncRNA expression has been associated with significant worse overall survival (pooled HR = 2.05, 95 % CI = 1.79–2.30, P <0.001), shorter disease-free survival (pooled HR = 2.17, 95 % CI = 1.13–3.22, P< 0.001), and lower complete remission rate (pooled HR = 0.27, 95 % CI = 0.11–0.43, P< 0.001). Poor prognoses have been attributed to increased expression of HOX transcript antisense intergenic RNA (HOTAIR), Promoter Of CDKN1A Antisense DNA Damage Activated RNA (PANDAR), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), RP11–222K16.2, Taurine Upregulated Gene 1 (TUG1), Small Nucleolar RNA Host Gene 5 (SNHG5), Growth Arrest Specific 5 (GAS5), and H19 and decreased expression of IGF1R Antisense Imprinted Non-Protein Coding RNA (IRAIN).

Conclusion

The prognoses of AML patients are significantly associated with abnormally expressed lncRNAs, which may be used as prognostic indicators for predicting the patient outcomes.

背景长非编码RNA（lncRNA）可作为急性髓性白血病（AML）的预后生物标志物。然而，目前尚不清楚lncRNA对急性髓性白血病预后的确切意义。本研究以其预后和治疗潜力为重点，旨在对有关lncRNAs在AML中作用的文献进行全面综述。研究方法检索了Pub Med、The Cochrane Library、Embase、Science Direct、Web of science、Scopus和Google scholar，直至2023年11月。纳入了探讨 lncRNAs 在急性髓细胞性白血病患者中的预后和治疗潜力的任何类型的原始出版物。分别使用 I2 检验和漏斗图检验异质性和发表偏倚。为了量化各种lncRNA表达与AML患者生存之间的关系，对带有95%置信区间（CI）的几率比（OR）或危险比（HR）进行了汇总。研究质量采用乔安娜-布里格斯研究所（JBI）制定的 "研究关键评估清单"（Critical Appraisal Checklists for Studies）进行评估。在急性髓细胞性白血病患者中，lncRNA表达异常与较差的总生存期（汇总HR = 2.05，95 % CI = 1.79-2.30，P<0.001）、较短的无病生存期（汇总HR = 2.17，95 % CI = 1.13-3.22，P<0.001）和较低的完全缓解率（汇总HR = 0.27，95 % CI = 0.11-0.43，P<0.001）明显相关。预后不良的原因是 HOX 转录本反义基因间 RNA（HOTAIR）、Promoter Of CDKN1A Antisense DNA Damage Activated RNA（PANDAR）、Metastasis Associated Lung Adenocarcinoma Transcript 1（MALAT1）、RP11-222K16.2、牛磺酸上调基因1（TUG1）、小核极RNA宿主基因5（SNHG5）、生长停滞特异性5（GAS5）和H19的表达以及IGF1R反义印迹非蛋白编码RNA（IRAIN）的表达减少。

{"title":"Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis","authors":"","doi":"10.1016/j.leukres.2024.107595","DOIUrl":"10.1016/j.leukres.2024.107595","url":null,"abstract":"<div><h3>Background</h3><div>Long noncoding RNAs (lncRNAs) may function as prognostic biomarkers in acute myeloid leukaemia (AML). However, it is still unknown exactly how significant lncRNAs are for the prognosis of AML. With a focus on their prognostic and therapeutic potential, the study aimed to provide a comprehensive review of the literature regarding the role of lncRNAs in AML.</div></div><div><h3>Method</h3><div>Pub Med, The Cochrane Library, Embase, Science Direct, Web of science, Scopus, and Google scholar were searched until November, 2023. Original publications of any type exploring the prognostic and therapeutic potential of lncRNAs in AML patients were included. Heterogeneity and publication bias were examined using the I<sup>2</sup> test and a funnel plot, respectively. To quantify the relationship between various lncRNA expression in AML patient survival, odds ratios (ORs) or hazards ratios (HRs) with 95 % confidence intervals (CIs) were pooled. Quality of studies was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI).</div></div><div><h3>Results</h3><div>Twenty-seven studies including 5665 subjects were selected for the final analysis. In patients with AML, abnormal lncRNA expression has been associated with significant worse overall survival (pooled HR = 2.05, 95 % CI = 1.79–2.30, P <0.001), shorter disease-free survival (pooled HR = 2.17, 95 % CI = 1.13–3.22, P< 0.001), and lower complete remission rate (pooled HR = 0.27, 95 % CI = 0.11–0.43, P< 0.001). Poor prognoses have been attributed to increased expression of HOX transcript antisense intergenic RNA (HOTAIR), Promoter Of CDKN1A Antisense DNA Damage Activated RNA (PANDAR), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), RP11–222K16.2, Taurine Upregulated Gene 1 (TUG1), Small Nucleolar RNA Host Gene 5 (SNHG5), Growth Arrest Specific 5 (GAS5), and H19 and decreased expression of IGF1R Antisense Imprinted Non-Protein Coding RNA (IRAIN).</div></div><div><h3>Conclusion</h3><div>The prognoses of AML patients are significantly associated with abnormally expressed lncRNAs, which may be used as prognostic indicators for predicting the patient outcomes.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Leukemia research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀